MENU
+Compare
CHGCF
Stock ticker: OTC
AS OF
Feb 3 closing price
Price
$54.16
Change
+$3.58 (+7.08%)
Capitalization
93.5B

CHGCF stock forecast, quote, news & analysis

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company... Show more

CHGCF
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for CHGCF with price predictions
Feb 02, 2026

CHGCF in upward trend: price rose above 50-day moving average on January 23, 2026

CHGCF moved above its 50-day moving average on January 23, 2026 date and that indicates a change from a downward trend to an upward trend. In of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 23, 2026. You may want to consider a long position or call options on CHGCF as a result. In of 70 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CHGCF just turned positive on January 26, 2026. Looking at past instances where CHGCF's MACD turned positive, the stock continued to rise in of 36 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for CHGCF crossed bullishly above the 50-day moving average on January 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CHGCF advanced for three days, in of 61 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHGCF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CHGCF broke above its upper Bollinger Band on January 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CHGCF entered a downward trend on January 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.840) is normal, around the industry mean (9.533). P/E Ratio (31.921) is within average values for comparable stocks, (24.433). Projected Growth (PEG Ratio) (3.146) is also within normal values, averaging (1.907). Dividend Yield (0.015) settles around the average of (0.025) among similar stocks. CHGCF's P/S Ratio (11.013) is very high in comparison to the industry average of (3.990).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CHGCF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHGCF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock worse than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Dividends

CHGCF paid dividends on August 30, 2021

Chugai Pharmaceutical Co., Ltd. CHGCF Stock Dividends
А dividend of $30.00 per share was paid with a record date of August 30, 2021, and an ex-dividend date of June 29, 2021. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 114.81B. The market cap for tickers in the group ranges from 72.83K to 898.12B. LLY holds the highest valuation in this group at 898.12B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -0%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 18%. AZN experienced the highest price growth at 93%, while NONOF experienced the biggest fall at -21%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 9%. For the same stocks of the Industry, the average monthly volume growth was 42% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 29
P/E Growth Rating: 65
Price Growth Rating: 49
SMR Rating: 55
Profit Risk Rating: 72
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
CHGCF
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
1-1 Nihonbashi-Muromachi 2-Chome
Phone
+81 332816611
Employees
7432
Web
http://www.chugai-pharm.co.jp